Martina Hrabinova

List of Publications by Year
in descending order

72	1,589	304368 22	344852 36
papers	citations	h-index	g-index

73	73	73	2001
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Assessment of Acetylcholinesterase Activity Using Indoxylacetate and Comparison with the Standard Ellmanâ€™s Method. International Journal of Molecular Sciences, 2011, 12, 2631-2640.	1.8	125
2	Tacrineâ€“Trolox Hybrids: A Novel Class of Centrally Active, Nonhepatotoxic Multi-Target-Directed Ligands Exerting Anticholinesterase and Antioxidant Activities with Low In Vivo Toxicity. Journal of Medicinal Chemistry, 2015, 58, 8985-9003.	2.9	121
3	Synthesis and Biological Evaluation of Novel Tacrine Derivatives and Tacrineâ€“Coumarin Hybrids as Cholinesterase Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 7073-7084.	2.9	99
4	Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 127, 250-262.	2.6	95
5	Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 168, 491-514.	2.6	75
6	Targeting copper(II)-induced oxidative stress and the acetylcholinesterase system in Alzheimer's disease using multifunctional tacrine-coumarin hybrid molecules. Journal of Inorganic Biochemistry, 2016, 161, 52-62.	1.5	63
7	Russian VX: Inhibition and Reactivation of Acetylcholinesterase Compared with VX Agent. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 389-394.	1.2	36
8	Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkageâ€”initial study for Myasthenia gravis implications. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1763-1766.	1.0	36
9	7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimerâ€™s Disease Treatment. Molecules, 2015, 20, 22084-22101.	1.7	35
10	Design, Synthesis and in vitro Evaluation of Indolotacrine Analogues as Multitargetâ€Directed Ligands for the Treatment of Alzheimer's Disease. ChemMedChem, 2016, 11, 1264-1269.	1.6	35
11	Alkaloids from Narcissus poeticus cv. Pink Parasol of various structural types and their biological activity. Archives of Pharmacal Research, 2018, 41, 208-218.	2.7	35
12	Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage â€“ Implications for early Myasthenia gravis treatment. European Journal of Medicinal Chemistry, 2011, 46, 811-818.	2.6	33
13	Novel Tacrine-Scutellarin Hybrids as Multipotent Anti-Alzheimerâ€™s Agents: Design, Synthesis and Biological Evaluation. Molecules, 2017, 22, 1006.	1.7	32
14	Isoquinoline Alkaloids from Fumaria officinalis L. and Their Biological Activities Related to Alzheimer's Disease. Chemistry and Biodiversity, 2016, 13, 91-99.	1.0	30
15	Diagnosis of Intoxication by the Organophosphate VX: Comparison Between an Electrochemical Sensor and EllmanÂ´s Photometric Method. Sensors, 2008, 8, 5229-5237.	2.1	28
16	Synthesis, design and biological evaluation of novel highly potent tacrine congenersÂfor the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2012, 55, 23-31.	2.6	27
17	Potency of new structurally different oximes to reactivate cyclosarin-inhibited human brain acetylcholinesterases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2006, 21, 663-666.	2.5	26
18	Oxime K027: novel low-toxic candidate for the universal reactivator of nerve agent- and pesticide-inhibited acetylcholinesterase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2010, 25, 509-512.	2.5	26

#	Article	IF	Citations
19	Development of 2-Methoxyhuprine as Novel Lead for Alzheimerâ€™s Disease Therapy. Molecules, 2017, 22, 1265.	1.7	26
20	Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile. European Journal of Medicinal Chemistry, 2020, 203, 112593.	2.6	24
21	Isoquinoline alkaloids as prolyl oligopeptidase inhibitors. FÃ¬toterapÃ¬Ã¢, 2015, 103, 192-196.	1.1	23
22	Isolation of Amaryllidaceae alkaloids from Nerine bowdenii W. Watson and their biological activities. RSC Advances, 2016, 6, 80114-80120.	1.7	23
23	Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors. Biomolecules, 2019, 9, 379.	1.8	23
24	In Vitro and In Silico Acetylcholinesterase Inhibitory Activity of Thalictricavine and Canadine and Their Predicted Penetration across the Blood-Brain Barrier. Molecules, 2019, 24, 1340.	1.7	23
25	Derivatives of the Î²-Crinane Amaryllidaceae Alkaloid Haemanthamine as Multi-Target Directed Ligands for Alzheimerâ€™s Disease. Molecules, 2019, 24, 1307.	1.7	22
26	Amaryllidaceae Alkaloids of Belladine-Type from Narcissus pseudonarcissus cv. Carlton as New Selective Inhibitors of Butyrylcholinesterase. Biomolecules, 2020, 10, 800.	1.8	21
27	Alkaloids of Zephyranthes citrina (Amaryllidaceae) and their implication to Alzheimer's disease: Isolation, structural elucidation and biological activity. Bioorganic Chemistry, 2021, 107, 104567.	2.0	20
28	Alkaloids from Chlidanthus fragrans and their acetylcholinesterase, butyrylcholinesterase and prolyl oligopeptidase activities. Natural Product Communications, 2013, 8, 1541-4.	0.2	20
29	Preparation of Benzalkonium Salts Differing in the Length of a Side Alkyl Chain. Molecules, 2007, 12, 2341-2347.	1.7	19
30	Cholinesterase and Prolyl Oligopeptidase Inhibitory Activities of Alkaloids from Argemone platyceras (Papaveraceae). Molecules, 2017, 22, 1181.	1.7	19
31	2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2021, 211, 113112.	2.6	19
32	In vitro and in silico Evaluation of Non-Quaternary Reactivators of AChE as Antidotes of Organophosphorus Poisoning - a New Hope or a Blind Alley?. Medicinal Chemistry, 2018, 14, 281-292.	0.7	19
33	Novel Bisquaternary Oximesâ€”Reactivation of Acetylcholinesterase and Butyrylcholinesterase Inhibited by Paraoxon. Molecules, 2009, 14, 4915-4921.	1.7	17
34	A Comparison of the Potency of the Oxime HLÃ¶-7 and Currently Used Oximes (HI-6, Pralidoxime,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Acta Medica (Hradec Kralove), 2005, 48, 81-86.	0.2	17
35	Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitorsâ€”Analogues of SAD-128. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 150-154.	1.0	16
36	Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2021, 12, 1698-1715.	1.7	16

#	Article	IF	Citations
37	Targeted Synthesis of 1-(4-Hydroxyiminomethylpyridinium)-3-pyridiniumpropane Dibromide â€“ A New Nerve Agent Reactivator. Molecules, 2007, 12, 1964-1972.	1.7	15
38	Revised NMR data for 9-O-demethylgalanthine: an alkaloid from Zephyranthes robusta (Amaryllidaceae) and its biological activity. Natural Product Communications, 2014, 9, 787-8.	0.2	15
39	Alkaloids from Chlidanthus fragrans and their Acetylcholinesterase, Butyrylcholinesterase and Prolyl Oligopeptidase Activities. Natural Product Communications, 2013, 8, 1934578X1300801.	0.2	14
40	Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17Î²-HSD10 with Implications to Alzheimerâ€™s Disease Treatment. International Journal of Molecular Sciences, 2020, 21, 2059.	1.8	14
41	Twelve Different HI-6 Salts and their Potency to Reactivate Cyclosarin Inhibited AChE In Vitro. Letters in Drug Design and Discovery, 2007, 4, 510-512.	0.4	13
42	Comparison ofin vitro potency of oximes (pralidoxime, obidoxime, HI-6) to reactivate sarin-inhibited acetylcholinesterase in various parts of pig brain. Journal of Applied Toxicology, 2005, 25, 271-276.	1.4	12
43	In VitroEvaluation of Acetylcholinesterase Reactivators as Potential Antidotes Against Tabun Nerve Agent Poisonings. Drug and Chemical Toxicology, 2006, 29, 443-449.	1.2	12
44	Asoxime (HI-6) impact on dogs after one and tenfold therapeutic doses: Assessment of adverse effects, distribution, and oxidative stress. Environmental Toxicology and Pharmacology, 2011, 32, 75-81.	2.0	11
45	Preparation, in vitro evaluation and molecular modelling of pyridiniumâ€“quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6663-6666.	1.0	11
46	Synthesis, Biological Evaluation, and Docking Studies of Novel Bisquaternary Aldoxime Reactivators on Acetylcholinesterase and Butyrylcholinesterase Inhibited by Paraoxon. Molecules, 2018, 23, 1103.	1.7	11
47	In Vitro Potency of H Oximes (HI-6, HLÃ¶-7), the Oxime BI-6, and Currently Used Oximes (Pralidoxime,) Tj ETQq1 1 0.784314 rgBT /Ov of Toxicology and Environmental Health - Part A: Current Issues, 2006, 69, 1431-1440.	1.1	9
48	The preparation, in vitro screening and molecular docking of symmetrical bisquaternary cholinesterase inhibitors containing a but-(2E)-en-1,4-diyl connecting linkage. Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, 26, 245-253.	2.5	9
49	Chemical composition of bioactive alkaloid extracts from some Narcissus species and varieties and their biological activity. Natural Product Communications, 2014, 9, 1151-5.	0.2	9
50	Alkaloids from Peumus boldus and their acetylcholinesterase, butyrylcholinesterase and prolyl oligopeptidase inhibition activity. Natural Product Communications, 2015, 10, 577-80.	0.2	9
51	New group of xylene linker-containing acetylcholinesterase reactivators as antidotes against the nerve agent cyclosarin. Journal of Enzyme Inhibition and Medicinal Chemistry, 2006, 21, 515-519.	2.5	8
52	Potency of Five Structurally Different Acetylcholinesterase Reactivators to Reactivate Human Brain Cholinesterases Inhibited by Cyclosarin. Clinical Toxicology, 2007, 45, 512-515.	0.8	8
53	Evaluation of Cholinesterase Activities During in Vivo Intoxication Using an Electrochemical Sensor Strip â€“ Correlation With Intoxication Symptoms. Sensors, 2009, 9, 3627-3634.	2.1	8
54	Reactivation of Human Brain Homogenate Cholinesterases Inhibited by Tabun using Newly Developed Oximes K117 and K127. Basic and Clinical Pharmacology and Toxicology, 2009, 105, 207-210.	1.2	8

#	Article	IF	Citations
55	Alkaloids from Peumus boldus and their Acetylcholinesterase, Butyrylcholinesterase and Prolyl Oligopeptidase Inhibition Activity. Natural Product Communications, 2015, 10, 1934578X1501000.	0.2	6
56	Tacrine and its 7-methoxy derivate; time-change concentration in plasma and brain tissue and basic toxicological profile in rats. Drug and Chemical Toxicology, 2021, 44, 207-214.	1.2	6
57	Chemical Composition of Bioactive Alkaloid Extracts from Some Narcissus Species and Varieties and their Biological Activity. Natural Product Communications, 2014, 9, 1934578X1400900.	0.2	5
58	Pharmacological and toxicological in vitro and in vivo effect of higher doses of oxime reactivators. Toxicology and Applied Pharmacology, 2019, 383, 114776.	1.3	5
59	Huprine Y â€“ Tryptophan heterodimers with potential implication to Alzheimerâ€™s disease treatment. Bioorganic and Medicinal Chemistry Letters, 2021, 43, 128100.	1.0	5
60	Amaryllidaceae Alkaloids of Norbelladine-Type as Inspiration for Development of Highly Selective Butyrylcholinesterase Inhibitors: Synthesis, Biological Activity Evaluation, and Docking Studies. International Journal of Molecular Sciences, 2021, 22, 8308.	1.8	5
61	Development of small bisquaternary cholinesterase inhibitors as drugs for pre-treatment of nerve agent poisonings. Drug Design, Development and Therapy, 2018, Volume 12, 505-512.	2.0	4
62	New Bisquaternary Isoquinolinium Inhibitors of Brain Cholinesterases - Synthesis and Anticholinesterase Activity. Letters in Drug Design and Discovery, 2010, 7, 1-4.	0.4	4
63	Structure-Activity Relationship for the Reactivators of Acetylcholinesterase Inhibited by Nerve Agent VX. Medicinal Chemistry, 2013, 9, 689-693.	0.7	4
64	Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats. Iranian Journal of Pharmaceutical Research, 2020, 19, 95-102.	0.3	4
65	ON THE UNIVERSALITY OF OXIME HLÃ¶-7 - ANTIDOTE FOR CASE OF THE NERVE AGENT POISONING. Military Medical Science Letters (Vojenske Zdravotnicke Listy), 2011, 80, 80-84.	0.2	4
66	Pursuing the Complexity of Alzheimerâ€™s Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-d-Aspartate Receptor Antagonists. Biomolecules, 2021, 11, 3.	1.8	4
67	Impact of paraoxon followed by acetylcholinesterase reactivator HI-6 on gastric myoelectric activity in experimental pigs. Neuroendocrinology Letters, 2013, 34 Suppl 2, 79-83.	0.2	4
68	Novel Nucleophilic Compounds with Oxime Group as Reactivators of Paraoxon-Inhibited Cholinesterases. Letters in Drug Design and Discovery, 2010, 7, 260-264.	0.4	3
69	Heterocyclic Cathinones as Inhibitors of Kynurenine Aminotransferase IIâ€”Design, Synthesis, and Evaluation. Pharmaceuticals, 2021, 14, 1291.	1.7	3
70	Impact of tacrine and 7-methoxytacrine on gastric myoelectrical activity assessed using electrogastrography in experimental pigs. Neuroendocrinology Letters, 2015, 36 Suppl 1, 150-5.	0.2	2
71	(+)-Chenabinol (Revised NMR Data) and Two New Alkaloids from Berberis vulgaris and their Biological Activity. Natural Product Communications, 2015, 10, 1934578X1501001.	0.2	1
72	TLC analysis of twelve different salts of oxime HI-6 â€” Reactivator of nerve agent inhibited AChE. Journal of Planar Chromatography - Modern TLC, 2011, 24, 105-107.	0.6	0